TYRA Stock Up 24% after 5-Day Win Streak
Tyra Biosciences (TYRA) stock hit day 5 of a continuous streak of days with gains, with cumulative gains over this period amounting to a 24% return. The company has gained about $180 Mil in value over the last 5 days, with its current market capitalization at about $753 Mil. The stock remains 9.1% below its value at the end of 2024. This compares with year-to-date returns of 9.9% for the S&P 500.
TYRA focuses on developing therapies to overcome tumor resistance and improve cancer patient outcomes, with a lead product targeting FGFR3 for muscle invasive bladder cancer treatment. After this rally, is TYRA still a buy – or is it time to lock in gains? Deep dive with Buy or Sell TYRA.
Comparing TYRA Stock Returns With The S&P 500
The following table summarizes the return for TYRA stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | TYRA | S&P 500 |
|---|---|---|
| 1D | 5.3% | 0.4% |
| 5D (Current Streak) | 23.9% | 0.9% |
| 1M (21D) | 13.8% | 1.2% |
| 3M (63D) | 43.3% | 9.2% |
| YTD 2025 | -9.1% | 9.9% |
| 2024 | 0.4% | 23.3% |
| 2023 | 82.2% | 24.2% |
| 2022 | -46.0% | -19.4% |
What is the point? Momentum often precedes conviction. A multi-day win streak can signal growing investor confidence or spark follow-on buying. Tracking such trends can help you ride the strength, or prepare for a well-timed entry if momentum fades. However, big gains can follow sharp reversals – but how has TYRA behaved after prior drops? See TYRA Dip Buyer Analysis to learn more.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 42 S&P constituents with 3 days or more of consecutive gains and 30 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 28 | 11 |
| 4D | 7 | 17 |
| 5D | 6 | 2 |
| 6D | 0 | 0 |
| 7D or more | 1 | 0 |
| Total >=3 D | 42 | 30 |
Key Financials for Tyra Biosciences (TYRA)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $0 | $0 |
| Operating Income | $-79.9 Mil | $-104.2 Mil |
| Net Income | $-69.1 Mil | $-86.5 Mil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ1 | 2025 FQ2 |
|---|---|---|
| Revenues | $0 | $0 |
| Operating Income | $-31.8 Mil | $-31.5 Mil |
| Net Income | $-28.1 Mil | $-28.1 Mil |
While TYRA stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.